Healthcare (SH:603313) Xin Lang Zheng Quan·2025-10-22 01:58Core Viewpoint - The stock price of Dream Lily has shown significant growth this year, with a notable increase in trading activity and institutional interest, indicating a positive market sentiment towards the company [2][3]. Stock Performance - As of October 22, Dream Lily's stock price increased by 2.08% to 9.83 CNY per share, with a trading volume of 1.17 billion CNY and a turnover rate of 2.12%, resulting in a total market capitalization of 56.09 billion CNY [1]. - Year-to-date, Dream Lily's stock price has risen by 46.72%, with a 15.24% increase over the last five trading days, 14.04% over the last 20 days, and 14.70% over the last 60 days [2]. Trading Activity - Dream Lily has appeared on the "Dragon and Tiger List" twice this year, with the most recent instance on October 17, where it recorded a net purchase of 37.19 million CNY, accounting for 28.31% of total trading volume [2]. - The net inflow of main funds was 3.07 million CNY, with large orders accounting for 17.25% of purchases and 13.30% of sales [1]. Financial Performance - For the first half of 2025, Dream Lily reported a revenue of 4.316 billion CNY, representing a year-on-year growth of 9.35%, and a net profit attributable to shareholders of 115 million CNY, which is a significant increase of 117.82% [3]. Shareholder Information - As of June 30, 2025, Dream Lily had 24,200 shareholders, a decrease of 1.33% from the previous period, with an average of 23,611 circulating shares per shareholder, an increase of 1.34% [3]. - The company has distributed a total of 546 million CNY in dividends since its A-share listing, with 28.53 million CNY distributed over the last three years [4]. Institutional Holdings - Notable new institutional shareholders include Hua'an Ankang Flexible Allocation Mixed A, which is the fourth largest shareholder with 9.83 million shares, and several other funds that have recently entered the top ten shareholders list [4].